Can a heart drug save lives in septic shock? new trial aims to find out.
NCT ID NCT04031573
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called ivabradine in 429 adults with septic shock, a life-threatening condition where infection causes dangerously low blood pressure. Many patients develop a fast heart rate, which can worsen outcomes. Ivabradine slows the heart without weakening its pumping strength, unlike standard beta-blockers. The goal is to see if controlling heart rate this way reduces deaths at 28 days.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPTIC SHOCK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Henri Mondor Hospital
Créteil, 94000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood markers may foretell brain fog after sepsis
- Can tracking immune chaos in sepsis reveal new treatment targets?
- Blood clot score may predict organ damage in septic shock
- Could a key hormone be missing in septic shock?
- Could a simple mineral cut the need for powerful blood-pressure drugs in septic shock?
- Blood filter could shield vessels in septic shock